Two patients (cases #5 and #6) with hormone receptor–positive breast cancer declined the recommended adjuvant hormone therapy: one progressed at 11 months and was alive at 19+ months, and the other continued to be recurrence free at 17+ months of follow-up (Fig. 1). The gene discussed is NR4A1; the disease is breast carcinoma.